Inflectra's U.S. Launch Incrementally Positive for Pfizer (PFE), Negative for AbbVie (ABBV) - BMO

October 18, 2016 7:08 AM EDT
Get Alerts PFE Hot Sheet
Price: $31.70 +2.46%

Rating Summary:
    13 Buy, 12 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade PFE Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

BMO Capital analyst, Alex Arfei, reiterated his Outperform rating on shares of Pfizer (NYSE: PFE) after announcing Inflectra's U.S. launch; 1.5 years earlier than expected.

The analyst highlighted 3 key takeaways:
1) The announcement is incrementally positive and the "at risk" launch is clearly indicative of Pfizer's confidence regarding the outcome of Remicade patent litigation.
2) The 15% discount relative to WAC price of Remicade is lower than expected; however, we expect Pfizer to provide additional discounts during negotiations with payers.
3) Pfizer's leadership in biosimilars is a key reason the analyst is bullish on the stock.

The flip side of this announcement is that the news is negative for AbbVie (NASDAQ: ABBV). The analyst has also been cautious regarding biosimilar risk for Abbott Laboratories's (NYSE: ABT) Humira.

price target of $40.00

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.

Shares of Pfizer closed at $32.50 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments

Related Entities

BMO Capital

Add Your Comment